U.S. IV Infusion Products Market is forecast to reach a value of US$ 10,238.5 Million at a CAGR of 3.8% between 2022 and 2028 | AngioDynamics Inc., Kimal, Terumo Corporation, Teleflex Inc., Becton Dickinson and Company

The U.S. IV infusion products market is expected to record a CAGR of 3.8% during 2021-2028 and was estimated to be valued at US$ 7,885.4 million in 2021. Infusion products are used for many different medical procedures, including blood transfusions, chemotherapy, and intravenous fluids and antibiotics.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4700

The U.S IV infusion products market is expected to grow at a faster pace. Infusion pumps are a common option for IV infusions in hospitals. They are operated manually by a trained user and are usually equipped with built-in software. The benefits of these pumps include their ease of use and their ability to deliver small volumes of medications. They are often less expensive than other forms of infusions. The FDA’s approvals for IV infusions are anticipated to fuel the market in the next few years.

Market Drivers  

Approval and launch of new products is expected to propel growth of the U.S. IV infusion products market over the forecast period. For example, Teleflex Inc., in June 2018, launched Arrowg+ard Blue Advance peripherally inserted central catheters at World Congress on Vascular Access 2018 in Copenhagen, Denmark.

Covid-19 Impact Analysis

The pandemic increased demand for infusion pumps for COVID-19 patients. In 2020, Flex Ltd. reported manufacturing five times as many infusion pumps, in order to cater to the rising demand.

According to the new guidance document, the U.S. FDA will not object to limited changes to the indications, functionality, hardware, software, design, or materials of devices used to support patients requiring continuous infusion therapy. The policy applies when a device is modified in a way that would typically necessitate a new 510(k) premarket submission.

Market Trends

Major players operating in the U.S. IV infusion products market are focused on adopting merger and acquisition strategies to expand their product portfolio. For example, ICU Medical Inc., in October 2016, acquired Hospira Infusion Systems, an infusion therapy division of Pfizer, Inc.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4700

Key Players

Major players operating in the U.S. IV infusion products market include, AngioDynamics Inc., AdvaCare Pharma, B. Braun Medical Inc., Becton Dickinson and Company,  Cook Group, CODAN Companies, EMED Technologies Corporation, Greiner Bio-One International GmbH, Kimal, Nipro Corporation, PL Medical Co., LLC, Smiths Group plc, Terumo Corporation, Teleflex Inc., and ZOLL Medical Corporation.

Key Takeaways

Major players operating in the U.S. IV infusion products market are focused on adopting merger and acquisition strategies to expand their product portfolio. For example, Becton, Dickinson and Company, in April 2017, acquired Caesarea Medical Electronics, an infusion pump systems manufacturer.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. IV Infusion Products Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: U.S. IV Infusion Products Industry Impact

Chapter 2 U.S. IV Infusion Products Competition by Types, Applications, and Top Regions and Countries
2.1 U.S. IV Infusion Products (Volume and Value) by Type
2.3 U.S. IV Infusion Products (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4  U.S. IV Infusion Products Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in U.S. IV Infusion Products Business
Chapter 6U.S. IV Infusion Products Market Forecast (2022-2028)
Chapter 7 Conclusions
Research Methodology